Adjuvant therapy for women with high-risk endometrial carcinoma
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference8 articles.
1. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up;Colombo;Radiother Oncol,2015
2. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial;de Boer;Lancet Oncol,2018
3. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer;Greven;Gynecol Oncol,2006
4. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies;Hogberg;Eur J Cancer,2010
5. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial;de Boer;Lancet Oncol,2016
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Development and validation of a nomogram for predicting recurrence-free survival in endometrial cancer: a multicenter study;Scientific Reports;2023-11-20
2. The Role of miRNAs in the Development, Proliferation, and Progression of Endometrial Cancer;International Journal of Molecular Sciences;2023-07-15
3. An integrated approach of network pharmacology, molecular docking, and experimental verification uncovers kaempferol as the effective modulator of HSD17B1 for treatment of endometrial cancer;Journal of Translational Medicine;2023-03-17
4. Construction of Endometrial Carcinoma ceRNA Network and Screening of Key Genes Based on TCGA Database;Computational and Mathematical Methods in Medicine;2022-07-04
5. miR-544a Stimulates endometrial carcinoma growth via targeted inhibition of reversion-inducing cysteine-rich protein with Kazal motifs;Molecular and Cellular Probes;2020-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3